Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer

Oncology Reports

Volumn 23, Issue 4, 2010, Pages 917-925

  Kusumoto, Tomoyuki ^a   Kodama, Junichi ^a   Seki, Noriko ^a   Nakamura, Keiichiro ^a   Hongo, Atsushi ^a   Hiramatsu, Yuji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Epithelial ovarian cancer; Prognosis; Syndecan 1; Versican

Indexed keywords

SYNDECAN 1; VERSICAN;

ADENOCARCINOMA; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STROMA;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; SYNDECAN-1; TUMOR MARKERS, BIOLOGICAL; VERSICANS;

EID: 77949451668     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000715     Document Type: Article

References (45)

1. Kresse H and Schonherr E: Proteoglycans of the extracellular matrix and growth control. J Cell Physiol 189: 266-274, 2001.
2. Bernfield M, Gotte M, Park PW, et al: Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68: 729-777, 1999.
3. Yanagishita M and Hascall VC: Cell surface heparan sulfate proteoglycans. J Biol Chem 267: 9451-9454, 1992.
4. Carey DJ: Syndecans: multifunctional cell-surface corecepters. Biochem J 327: 1-16, 1997.
5. Bernfield M, Kokenyesi R, Kato M, et al: Biology of syndecans. Annu Rev Cell Biol 8: 365-393, 1992.
6. Sanderson RD, Hinkes M and Bernfield M: Syndecan-1, a cell surface proteoglycan, changes in size and abundance when keratinocytes stratify. J Invest Dermatol 99: 390-396, 1992.
7. Liebersbach BF and Sanderson RD: Expression of syndecan-1 inhibits cell invasion into type I collagen. J Biol Chem 269: 20013-20019, 1994.
8. Leppa S, Mali M, Miettinen HM, et al: Syndecan expression regulates cell morphology and growth of mouse mammary epithelial tumor cells. Proc Natl Acad Sci USA 189: 932-936, 1992.
9. Inki P, Stenback F, Talve L, et al: Immunohistochemical localization of syndecan in mouse skin tumors induced by UV irradiation. Loss of expression associated with malignant transformation. Am J Pathol 139: 1333-1340, 1991.
10. Fujiya M, Watari J, Ashida T, et al: Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn J Cancer Res 92: 1074-1081, 2001.
11. Wiksten JP, Lundin J, Nordling S, et al: Epithelial and stromal sundecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer 95: 1-6, 2001.
12. Anttonen A, Kajanti M, Heikkila P, et al: Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer 79: 558-564, 1999.
13. Klatka J: Syndeca-1 expression in laryngeal cancer. Eur Arch Otorhinolaryngol 259: 115-118, 2002.
14. Stah L, Walter KL, Borczuk AC, et al: Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with non-small cell lung carcinoma. Cancer 101: 1632-1638, 2004.
15. Harada K, Masuda S, Hirano M, et al: Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Hum Pathol 34: 857-863, 2003.
16. Kumar-Singh S, Jacobs W, Dhaene K, et al: Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol 186: 300-305, 1998.
17. Hasengaowa, Kodama J, Kusumoto T, et al: Prognostic significance of syndecan-1 expression in human endometrial cancer. Ann Oncol 16: 1109-1115, 2005.
18. Leivonen M, Lundin J, Nordling S, et al: Prognostic value of syndecan-1 expression in breast cancer. Oncology 67: 11-18, 2004.
19. Máthé M, Suba Z, Németh Z, et al: Stromal syndecan-1 expression is an adverse prognostic factor in oral carcinomas. Oral Oncol 42: 493-500, 2006.
20. Schwartz NB, Pirok EW III, Maensch JR Jr, et al: Domain organization, genomic structure, evolution, and regulation of expression of the aggrecan gene family. Proc Nucleic Acid Res Mol Biol 62: 177-223, 1999.
21. Dours-Zimmermann MT and Zimmermann DR: A novel glycosaminoglycan attachment domain in identified in two alternative splice variants of human versican. J Biol Chem 269: 32992-3298, 1994.
22. Ito K, Shinomura T, Zako M, et al: Multiple forms of mouse PG-M, a large chondroitin sulfate proteoglycans generated by alternative splicing. J Biol Chem 270: 958-965, 1995.
23. Zako M, Shinomura T, Ujita M, et al: Expression of PG-M (V3), an alternatively spliced form of PG-M without a chondroitin sulfate attachment in region in mouse and human tissues. J Biol Chem 270: 3914-3918, 1995.
24. Theocharis AD, Tsara ME, Papageorgacopoulou N, et al: Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. Biochim Biophys Acta 1502: 201-206, 2000.
25. Theocharis AD: Human colon adenocarcinoma is associated with specific post-translational modifications of versican and decorin. Biochim Biophys Acta 1588: 165-172, 2002.
26. Skandalis S, Theocharis AD, Theocharis DA, et al: Matrix proteoglycans are markedly affected in advanced laryngeal squamous cell carcinoma. Biochim Biophys Acta 1689: 152-161, 2004.
27. Sakko AJ, Ricciardelli C, Mayne K, et al: Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Res 61: 926-930, 2001.
28. Suwiwat S, Ricciardelli C, Tammi R, et al: Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 10: 2491-2498, 2004.
29. Pirinen R, Leinonen T, Böhm J, et al: Versican in non-small cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Human Pathol 36: 44-50, 2005.
30. Ricciardelli C, Mayne K, Sykes PJ, et al: Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res 4: 963-971, 1998.
31. Pukkila M, Kosunen A, Ropponen K, et al: High stromal versican expression predicts unfavorable outcome in oral squamous cell carcinoma. J Clin Pathol 60: 267-272, 2006.
32. Kodama J, Hasengaowa, Kusumoto T, et al: Prognostic significance of stromal versican expression in human endometrial cancer. Ann Oncol 18: 269-274, 2007.
33. Ruoslahti E: Integrins. J Clin Invest 87: 1-5, 1991.
34. Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251: 1451-1455, 1991.
35. Wight T, Kinsella MG and Qwarnstrom EE: The role of proteoglycans in cell adhesion, migration and proliferation. Curr Opin Cell Biol 4: 793-801, 1992.
36. Davies EJ, Blackhall FH, Shanks JH, et al: Distribution and clinical significance of heparin sulfate proteoglycans in ovarian cancer. Clin Cancer Res 10: 5178-5186, 2004.
37. Kato M, Saunders S, Nguyen H, et al: Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell 6: 559-576, 1995.
38. Stanley MJ, Staley MW, Sanderson RD, et al: Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol 112: 377-383, 1999.
39. Maeda T, Alexander CM and Friedl A: Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cell. Cancer Res 64: 612-621, 2004.
40. Kodama J, Hasengaowa, Kusumoto T, et al: Versican expression in human cervical cancer. Eur J Cancer 43: 1460-1466, 2007.
41. Hanekamp EE, Gielen SCJP, Smid-Koopman E, et al: Consequence of loss of progesterone receptor expression in development of invasive endometrial cancer. Clin Cancer Res 9: 4190-4199, 2003.
42. Ang LC, Zang Y, Cao L, et al: Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 domain. J Neuropathol Exp Neurol 58: 597-605, 1999.
43. Yang BL, Zhang Y, Cao L, et al: Cell adhesion and proliferation mediated through the G1 domain of versican. J Cell Biochem 72: 210-220, 1999.
44. Casey RC, Oegema TR Jr, Skubitz KM, et al: Cell membrane glycosylation mediate the adhesion, migration, and invasion of ovarian carcinoma cells. Clin Exp Metastasis 20: 143-152, 2003.
45. Voutilainen K, Anttila M, Sillanpaa S, et al: Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis. Int J Cancer 107: 359-364, 2003.